Real-World Data in Children with Spinal Muscular Atrophy Type 1 on Long-Term Ventilation Receiving Gene Therapy: A Prospective Cohort Study
Advances in Respiratory Medicine · 2024
DOI: 10.3390/arm92050032 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Advances in Respiratory Medicine, 2024. Verfasst von Mohammad Ala' Alajjuri und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. Hauptthemen laut MEDLINE: Spinal Muscular Atrophies of Childhood, Genetic Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Patients with spinal muscular atrophy type 1 (SMA-1) requiring invasive ventilation can be eligible for gene therapy if they tolerate at least 8 h off ventilation per day. We aimed to assess the short-term safety and efficacy of gene therapy (onasemnogene abeparvovec; Zolgensma) on respiratory function in SMA-1 patients ventilated via tracheostomy pre-gene therapy. A prospective cohort study included 22 patients. Patients were weaned off ventilation for at least 8 h daily by optimizing ventilator settings and duration, using cough augmentation, managing excessive airway secretions, enhancing nutrition, screening for respiratory bacterial colonization, and treating infections. Gene therapy was administered at a median age of 26 (Q1: 18, Q3: 43) months with a mean follow-up period of 7.64 (SD: 6.50) months. Gene therapy was safe and effective in resolving paradoxical breathing, improving cough ability, reducing airway secretions, and enhancing CHOP-INTEND scores. The clinical assessment and management implemented pre-gene therapy were effective in safely weaning patients for at least 8 h off ventilation daily. Gene therapy at a late age was safe and effective over the short-term period; however, long-term follow-up is recommended. In conjunction with gene therapy, high-quality clinical care is beneficial and should be paired with gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
- Dubai Health, Dubai, United Arab Emirates.
- Department of Pediatric Pulmonology, Mediclinic City Hospital, Dubai, United Arab Emirates.
- Department of Pediatric Neuroscience, Aster DM Healthcare, Medcare Women and Children Hospital, Dubai, United Arab Emirates.
- Department of Pediatric Pulmonology, American Hospital, Dubai, United Arab Emirates.
ORCID-Profile: Mohammad Ala' Alajjuri, Vivek Mundada
Zitieren
APA
Alajjuri, M. A., Abusamra, R., Mundada, V., & Narayan, O. (2024). Real-World Data in Children with Spinal Muscular Atrophy Type 1 on Long-Term Ventilation Receiving Gene Therapy: A Prospective Cohort Study. Advances in Respiratory Medicine. https://doi.org/10.3390/arm92050032
Vancouver
Alajjuri MA, Abusamra R, Mundada V, Narayan O. Real-World Data in Children with Spinal Muscular Atrophy Type 1 on Long-Term Ventilation Receiving Gene Therapy: A Prospective Cohort Study. Advances in Respiratory Medicine. 2024. doi:10.3390/arm92050032
BibTeX
@article{Alajjuri2024,
author = {Alajjuri, Mohammad Ala' and Abusamra, Rania and Mundada, Vivek and Narayan, Omendra},
title = {Real-World Data in Children with Spinal Muscular Atrophy Type 1 on Long-Term Ventilation Receiving Gene Therapy: A Prospective Cohort Study},
journal = {Advances in Respiratory Medicine},
year = {2024},
doi = {10.3390/arm92050032}
}
EUVIMED